渡利 英道 わたり ひでみち 先生

来歴等

略歴

1989年 北海道大学 医学部医学科 卒業
1995年 北海道大学大学院 医学研究科 博士課程 修了
2001年 北海道大学病院 婦人科 助手
2006年 北海道大学病院 婦人科 講師
2015年 北海道大学病院 婦人科 准教授
2018年 北海道大学大学院 医学研究院 産婦人科学教室 教授 現在に⾄る

論文

• 1. Comparison between Urine and Cervical High-Risk HPV Tests for Japanese Women with ASC-US. Diagnostics (Basel). 2021;11(10):1895.

  Yamazaki H, Wada T, Asano H, Fujita H. Okamoto K, Watari H.

• 2. Lymphadenectomy issues in endometrial cancer. J Gynecol Oncol. 2021 Mar;32(2): e25.

  Konno Y, Asano H, Shikama A, Aoki D, Tanikawa M, Oki A, Horie K, Mitsuhashi A, Kikuchi A, Tokunaga H, Terao Y, Satoh T, Ushijima K, Ishikawa M, Yaegashi N, *Watari H.

• 3. Long non-coding RNA DLEU2 drives EMT and glycolysis in endometrial cancer through HK2 by competitively binding with miR-455 and by modulating the EZH2/miR-181a pathway. J Exp Clin Cancer Res. 2021;40(1):216.

  Dong P, Xiong Y, Konno Y, Ihira K, Kobayashi N, Yue J, Watari H.

• 4. MicroRNA-361-Mediated Inhibition of HSP90 Expression and EMT in Cervical Cancer Is Counteracted by Oncogenic lncRNA NEAT1. Cells. 2020;9(3):632.

  Xu D, Dong P, Xiong Y, Yue J, Konno Y, Ihira K, Kobayashi N, Todo Y, Watari H.

• 5. Four versus six chemotherapy cycles in endometrial carcinoma with a high risk of recurrence: a retrospective study. Jpn J Clin Oncol. 2020;50(8):882-8.

  Mayama M, Asano H, Nomura E, Ihira K, Nozaki A, Kato T, Konno Y, Mitamura T, Kobayashi N, Takeda M, Kudo M, *Watari H.

• 6. L1CAM Predicts Adverse Outcomes in Patients with Endometrial Cancer Undergoing Full Lymphadenectomy and Adjuvant Chemotherapy. Ann Surg Oncol. 2020;27(7):2159-68.

  Asano H, Hatanaka KC, Matsuoka R, Dong P, Mitamura T, Konno Y, Kato T, Kobayashi N, Ihira K, Nozaki A, Oku A, Matsuno Y, Hatanaka Y, *Watari H.

• 7. Long noncoding RNA NEAT1 drives aggressive endometrial cancer progression via miR-361-regulated networks involving STAT3 and tumor microenvironment-related genes. J Exp Clin Cancer Res. 2019;38(1):295-310.

  Dong P, Xiong Y, Yue J, Xu D, Ihira K, Konno Y, Kobayashi N, Todo Y, Watari H.

• 8. Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer. Oncogene. 2018; 37(39):5257-68.

  Dong P, Xiong Y, Yu J, Chen L, Tao T, Yi S, Hanley SJB, Yue J, Watari H, Sakuragi N.

• 9. Additive effect of rikkunshito, an herbal medicine, on chemotherapy-induced nausea, vomiting, and anorexia in uterine cervical or corpus cancer patients treated with cisplatin and paclitaxel: results of a randomized phase II study (JORTC KMP-02). J Gynecol Oncol. 2017 Sep;28(5):e44.

  Ohnishi S, Watari H, Kanno M, Ohba Y, Takeuchi S, Miyaji T, Oyamada S, Nomura E, Kato H, Sugiyama T, Asaka M, Sakuragi N, Yamaguchi T, Uezono Y, Iwase S

• 10. Preoperative assessment of lymph node metastasis in endometrial cancer (PALMEC): a Korean Gynecologic Oncology Group study. Cancer. 2017; 123: 263-272.

  Kang S, Nam JH, Bae DS, Kim JW, Kim MH, Chen X, No JH, Lee JM, Kim JH, Watari H, Kim SM, Kim SH, Seong SJ, Kim KT, Kim SC, Kim JH, Lim MC, Lee JY, Ryu SY, Bingyi Y, Kim BG

• 11. EZH2 inhibition suppresses endometrial cancer progression via miR-361/Twist axis. Oncotarget. 2017;8(8):13509-13520.

  Ihira K, Dong P, Xiong Y, *Watari H, Konno Y, Hanley SJB, Noguchi M, Hirata N, Suizu F, Yamada T, Kudo M, Sakuragi N

• 12. MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells. Oncotarget. 2014;5: 6049-6062.

  Konno Y, Dong P, Xiong Y, Suzuki F, Lu J, Cai M, Watari H, Mitamura T, Hosaka M, Hanley SJ, Kudo M, Sakuragi N

• 13. Lymphadenectomy can be omitted for low-risk endometrial cancer based on preoperative assessments. J. Gynecol. Oncol. 2014; 25: 301-305.

  Mitamura T, *Watari H, Todo Y, Odagiri T, Kato T, Hosaka M, Kobayashi N, Sudo S, Takeda M, Dong P, Kudo M, Sakuragi N

• 14. miR-31 is an endometrial cancer oncogene that targets LATS2 and suppresses hippo tumor suppressor pathway. Mol. Cancer. 2014; 13: 97.

  Mitamura T, *Watari H, Wang L, Kanno H, Hassan MK, Miyazaki M, Katoh Y, Kimura T, Tanino M, Nishihara H, Tanaka S, Sakuragi N

• 15. Distribution of lymph node metastasis sites in endometrial cancer patients who underwent systematic pelvic and para-aortic lymphadenectomy-A proposal of optimal lymphadenectomy for future clinical trials- . Ann. Surg. Oncol. 2014; 21: 2755-2761.

  Odagiri T, *Watari H, Kato T, Mitamura T, Konno Y, Hosaka M, Kobayashi N, Sudo S, Takeda M, Todo Y, Dong P, Sakuragi N

• 16. Impact of FDG-PET in optimizing patient selection for cytoreductive surgery in recurrent ovarian cancer. Eur. J. Nucl. Med. Mol. Imaging. 2014; 41: 446-451.

  Ebina Y, Watari H, Kaneuchi M, Takeda M, Hosaka M, Kudo M, Yamada H, Sakuragi N

• 17. Multivariate prognostic analysis on the patients with adenocarcinoma of the uterine cervix treated with radical hysterectomy and systematic lymphadenectomy. J. Gynecol. Oncol. 2013; 24: 222-228.

  Kato T, *Watari H, Takeda M, Hosaka M, Mitamura T, Kobayashi N, Sudo S, Kaneuchi M, Kudo M, Sakuragi N

• 18. Clinical significance of tumor volume in endometrial cancer: A Japan-Korea cooperative study. Gynecol. Oncol. 2013; 131: 294-298.

  Todo Y, Choi HJ, Kang S, Kim JW, Nam JH, Watari H, Tamakoshi A, Sakuragi N

• 19. A low-risk group for lymph node metastasis is accurately identified by Korean Gynecologic Oncology Group criteria in two Japanese cohorts with endometrial cancer. Gynecol. Oncol. 2013; 129: 33-37

  Kang S, Todo Y, Odagiri T, Mitamura T, *Watari H, Kim JW, Nam JH, Sakuragi N

• 20. Downregulation of miR-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET. Oncogenesis. 2013; 2: e40.

  Mitamura T, *Watari H, Wang L, Kanno H, Hassan MK, Miyazaki M, Katoh Y, Kimura T, Tanino M, Nishihara H, Tanaka S, Sakuragi N

• 21. Incidence risk of cervical intraepithelial neoplasia 3 or more severe lesions is a function of human papillomavirus genotypes and severity of cytological and histological abnormalities in adult Japanese women. Int. J. Cancer. 2013; 132: 327-334.

  Hosaka M, Fujita H, Hanley SJB, Sasaki T, Shirakawa Y, Abiko M, Kudo M, Kaneuchi M, Watari H, Kikuchi K, Sakuragi N

• 22. Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene. 2013; 32: 3286-3295.

  Dong P, Karaayvazb M, Jia N, Kaneuchi M, Hamada J, Watari H, Sudo S, Ju J, Sakuragi N

• 23. New revised FIGO 2008 staging for endometrial cancer produces better discrimination in survival compared with the 1988 staging system. J. Surg. Oncol. 2012; 106: 938-941.

  Kato T, *Watari H, Endo D, Mitamura T, Odagiri T, Konno Y, Hosaka M, Kobayashi N, Todo Y, Sudo S, Takeda M, Dong P, Kaneuchi M, Kudo M, Sakuragi N

• 24. Clinical efficacy of paclitaxel/cisplatin as an adjuvant chemotherapy for patients who underwent radical hysterectomy and systematic lymphadenectomy. J. Surg. Oncol. 2012; 105: 612-616.

  Hosaka M, *Watari H, Kato T, Odagiri T, Konno Y, Mitamura T, Kikawa S, Suzuki Y, Sakuragi N

• 25. MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. Mol. Cancer 2011; 10: 99.

  Dong P, Kaneuchi M, Watari H, Hamada J, Sudo S, Ju J, Sakuragi N

• 26. Multivariate survival analysis of the patients with recurrent endometrial cancer. J. Gynecol. Oncol. 2011; 22: 3-8.

  Odagiri T, *Watari H, Hosaka M, Mitamura T, Konno Y, Kato T, Kobayashi N, Sudo S, Takeda M, Kaneuchi M, Sakuragi N

• 27. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a comparative cohort analysis. Lancet. 2010; 375 (9721): 1165-1172.

  Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N

• 28. Survival and prognosticators of node-positive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomy. Int. J. Clin. Oncol. 2011;16: 33-38.

  Hosaka M, Watari H, Konno Y, Odagiri T, Kato T, Takeda M, Sakuragi N

• 29. Clusterin predicts survival of invasive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomy. Gynecol. Oncol. 2008;108: 527-532.

  *Watari H, Ohta Y Hassan MK, Xiong Y, Tanaka S, Sakuragi N

• 30. A validation study of a scoring system to estimate the risk of lymph node metastasis for patients with endometrial carcinoma for tailoring the indication of lymphadenectomy. Gynecol. Oncol. 2007;104: 623-628.

  Todo Y, Okamoto K, Hayashi M, Minobe S, Nomura E, Hareyama H, Takeda M, Ebina Y, Watari H, Sakuragi N

• 31. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer. Gynecol. Oncol. 2005; 96: 651-657.

  *Watari H, Todo Y, Takeda M, Ebina Y, Yamamoto R, Sakuragi N

受賞

• 1. 2017年度 北海道産科婦⼈科学会 ⼤野学術奨励賞

• 2. 2019年度 北海道⼤学⼤学院医学研究院 優秀研究賞